KPV
Anti-inflammatory tripeptide derived from alpha-MSH for gut and systemic healing.
Key Benefits
blocks the master inflammatory signaling pathway at the cellular level
shown to reduce intestinal inflammation in IBD research models
accelerates tissue repair and reduces inflammatory scarring
active via oral, topical, and injectable administration
Active Signaling Pathway
Investigated Pathways
Proposed Mechanism
KPV exerts anti-inflammatory effects by directly entering cells and inhibiting NF-κB activation — the master regulator of inflammatory gene expression. It also acts on melanocortin receptors (MC1R, MC3R) to suppress pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6).
Research Highlights
- Shown to reduce colitis severity by 60–70% in murine IBD models
- Demonstrated direct cellular uptake — can act intracellularly without receptor binding
- Effective via oral, topical, and injectable routes in preclinical studies
- Shown to accelerate wound healing and reduce scar formation
Human observational or open-label study data exists. Controlled trial data may be limited. Not a treatment recommendation.
For research use only — not for human consumption. No treatment claims.
Full Research Hub →Recommended Stacks
KPV is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
Wolverine Recovery Stack
The gold-standard dual-peptide repair protocol — BPC-157 + TB-500 for connective tissue, muscle, and systemic healing.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 5mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
KPV exerts anti-inflammatory effects by directly entering cells and inhibiting NF-κB activation — the master regulator of inflammatory gene expression. It also acts on melanocortin receptors (MC1R, MC3R) to suppress pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6).
Clinical Context
KPV is particularly relevant for gut inflammation research. Its ability to be absorbed orally and act directly on intestinal epithelial cells makes it unique among anti-inflammatory peptides.
Research Highlights
- Shown to reduce colitis severity by 60–70% in murine IBD models
- Demonstrated direct cellular uptake — can act intracellularly without receptor binding
- Effective via oral, topical, and injectable routes in preclinical studies
- Shown to accelerate wound healing and reduce scar formation
Storage & Reconstitution
Store at -20°C. Reconstitute with 1 mL bacteriostatic water → 5 mg/mL. Stable 4 weeks at 2–8°C.
Key Studies
KPV tripeptide reduces intestinal inflammation in a murine model of colitis
Dalmasso G et al.
KPV reduced colitis severity by 60–70% in murine IBD models via NF-κB inhibition and direct cellular uptake.
PubMed →Anti-inflammatory effects of the alpha-MSH tripeptide KPV
Kannengiesser K et al.
KPV demonstrated potent anti-inflammatory effects via MC1R activation and NF-κB inhibition in multiple inflammatory models.
PubMed →KPV accelerates wound healing and reduces scar formation
Brzoska T et al.
KPV accelerated wound closure and reduced inflammatory scarring in skin wound models.
PubMed →Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Anti-inflammatory signaling in immune cells and skin
Blocks master inflammatory transcription factor, reducing cytokine production
Reduces pro-inflammatory cytokine levels at injury and inflammation sites
Maintains gut mucosal integrity and reduces intestinal permeability
Side Effects & Adverse Events
- Mild injection site reactions
- Transient nausea (oral)
- Headache
- Fatigue
- None documented in research
Contraindications & Interactions
Synergistic Compounds
KPV's NF-κB inhibition complements BPC-157's gut mucosal healing for comprehensive IBD and leaky gut research.
KPV 500 mcg oral + BPC-157 250 mcg SubQ, once or twice daily.
View Compound →Glutathione's antioxidant protection complements KPV's anti-inflammatory action for comprehensive gut and systemic healing.
KPV 1 mg oral + Glutathione 200 mg SubQ, daily.
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States